Metformin-Regulated Mitochondrial Peptides and their Effects on Aging
二甲双胍调节的线粒体肽及其对衰老的影响
基本信息
- 批准号:10665678
- 负责人:
- 金额:$ 41.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AgingAntidiabetic DrugsAttenuatedBioinformaticsBlood GlucoseCell LineChronicClinicalCollaborationsComplexCytoprotectionData SetDiseaseFatty acid glycerol estersGene Expression ProfileGenotypeHepatocyteHigh Fat DietHumanIn VitroIndividualInflammationInflammatoryLiverLongevityMediatingMetabolismMetforminMitochondriaMitochondrial DNAMusMuscleNamesNon-Insulin-Dependent Diabetes MellitusOpen Reading FramesPathway interactionsPeptidesPrincipal InvestigatorProductionRNAReactive Oxygen SpeciesRegulationRespiratory ChainRiskScandinavianSignal TransductionSingle Nucleotide PolymorphismSmall Interfering RNASystemTestingTherapeuticTissuesTranscriptVariantWeightWeight Gainage effectage relatedagedanti agingcell typecohortcytokinediabeticdrug candidatefour-arm studygenome wide association studyglucose metabolismhealthspanimprovedin vivoknock-downliver biopsymiddle agemimeticsmitochondrial genomemodel organismnovelnovel markerpeptidomimeticsresponsetranscriptometranscriptome sequencing
项目摘要
Metformin has healthspan and lifespan enhancing effects in model organisms and is a candidate therapy for
aging in humans. The exact mechanism of action of metformin is poorly understood, but the mitochondrion is
clearly a critical metformin target involving modulation of respiratory-chain function attributed to inhibition of
Complex-1 as well as other mitochondrial actions on fission, reactive oxygen species production, etc. Our lab
described the presence of multiple small open reading frames (smORFs) within mitochondrial DNA that
encode a novel class of mitochondrial-derived peptides (MDPs). These MDPs have diverse cellular actions,
often leading to improved metabolism, cytoprotection, and healthspan. We also demonstrated that
mitochondrial single nucleotide polymorphisms (mtSNPs) within these MDPs change their activity and increase
risk of aging-related diseases. Recently, we developed a novel bioinformatic approach to assess changes in
the expression of the entire mitochondrial smORFome called MDPseq. Using MDPSeq, we can demonstrate
profound changes in the expression of MDPs in disease states as well as during aging. We re-analyzed
multiple publicly available RNAseq datasets of humans and mice treated with metformin and observed
dramatic changes in the MDP smORF RNA transcript levels. After synthesizing the MDPs most potently
regulated by metformin and comparing them to metformin in several in vitro systems, we identified a number of
candidate metformin-induced MDPs that act in a metformin-mimetic fashion. One of these MDPs, named
Metformin-stimulated Mitochondrial-Derived Peptide (Ms.MDP), has similar activity to metformin on glucose
metabolism, mitochondrial function, and AMPK signaling. Ms.MDP siRNA diminishes some of metformin
actions. When administered to mice fed a high-fat diet, Ms.MDP significantly attenuated weight-gain and
dramatically reduced blood sugar, ALT, AST, and multiple inflammatory cytokines similarly – or more potently –
than metformin. Thus, we hypothesize that a key mechanism of metformin is MDP regulation, and that these
metformin-regulated MDPs mediate some of the functions of metformin. We further hypothesize that MDPs are
crucially involved in the anti-aging effects of metformin, which in turn can potentially help define individuals that
will respond to metformin and possibly serve as alternative healthspan-enhancing treatments. Our specific
aims to test this are as follows: 1: Identify human MDP smORF RNA transcripts in liver that are regulated by
metformin, and mitochondrial DNA variants that determine the clinical response to metformin in several large
human cohorts. 2: Compare the effects of aging and metformin on the MDP expression signature in mice. 3:
Characterize the aging-related effects of metformin-regulated MDPs in vitro, in various cell types, and 4:
Examine the in vivo mechanisms and therapeutic potential of chronic administration of promising metformin-
regulated MDPs in aged mice. Together, these studies will define a completely novel direction in
understanding the actions of metformin on delaying aging, and will establish novel biomarkers as well as
complementary/alternative anti-aging approaches.
二甲双胍在模式生物中具有延长健康和寿命的作用,是一种候选疗法
人类的衰老。二甲双胍的确切作用机制尚不清楚,但线粒体是
显然,一个关键的二甲双胍靶点涉及呼吸链功能的调节,归因于抑制
Complex-1以及其他线粒体在分裂、活性氧产生等方面的作用
描述了线粒体DNA中存在多个小开放阅读框(SmORF),
编码一类新的线粒体衍生多肽(MDP)。这些MDP有不同的细胞活动,
通常导致新陈代谢、细胞保护和健康寿命的改善。我们还展示了
这些MDP中的线粒体单核苷酸多态(MtSNPs)改变了它们的活性并增加了它们的活性
与衰老有关的疾病的风险。最近,我们开发了一种新的生物信息学方法来评估
整个线粒体smORFome的表达称为MDPseq。使用MDPSeq,我们可以演示
MDP在疾病状态和衰老过程中表达的深刻变化。我们重新分析了
多个公开可用的人类和小鼠二甲双胍治疗和观察的RNAseq数据集
MDP smORF RNA转录水平的戏剧性变化。在最有效地合成MDP之后
在几个体外系统中,我们发现了一些由二甲双胍调节的,并将它们与二甲双胍进行比较
候选的二甲双胍诱导的MDP以二甲双胍仿制的方式发挥作用。其中一位MDP,名叫
二甲双胍刺激的线粒体衍生多肽(Ms.MDP)具有与二甲双胍相似的葡萄糖活性
代谢、线粒体功能和AMPK信号转导。Ms.MDP siRNA减少部分二甲双胍
行为。当给喂高脂饮食的小鼠服用MDP时,MDP显著减缓了体重的增加和
显著降低血糖、丙氨酸氨基转移酶、天冬氨酸氨基转移酶和多种炎症细胞因子--类似地--或者更有效地--
而不是二甲双胍。因此,我们假设二甲双胍的一个关键机制是MDP调节,并且这些
二甲双胍调节的MDP介导了二甲双胍的一些功能。我们进一步假设MDP是
关键参与了二甲双胍的抗衰老作用,它反过来又可能有助于定义
将对二甲双胍有反应,并可能作为增强健康寿命的替代疗法。我们的特定
其目的如下:1:鉴定肝脏中受MDP调控的人mdp smORF RNA转录本
以及决定临床对二甲双胍疗效的线粒体DNA变异体
人类群体。2:比较衰老和二甲双胍对小鼠MDP表达特征的影响。3:
在不同细胞类型的体外实验中,表征二甲双胍调节的MDP的衰老相关效应,以及4:
探讨二甲双胍长期给药的体内机制和治疗潜力。
调节衰老小鼠的MDP。总之,这些研究将定义一个全新的方向
了解二甲双胍延缓衰老的作用,将建立新的生物标志物以及
互补/替代的抗衰老方法。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Plasma proteomics show altered inflammatory and mitochondrial proteins in patients with neurologic symptoms of post-acute sequelae of SARS-CoV-2 infection.
血浆蛋白质组学显示,患有 SARS-CoV-2 感染急性后遗症的神经系统症状的患者的炎症和线粒体蛋白发生了改变。
- DOI:10.1016/j.bbi.2023.08.022
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Hanson,BarbaraA;Visvabharathy,Lavanya;Orban,ZacharyS;Jimenez,Millenia;Batra,Ayush;Liotta,EricM;DeLisle,RobertK;Klausner,JeffreyD;Cohen,Pinchas;Padhye,AdvaitS;Tachas,George;Koralnik,IgorJ
- 通讯作者:Koralnik,IgorJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pinchas Cohen其他文献
Pinchas Cohen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pinchas Cohen', 18)}}的其他基金
Metformin-Regulated Mitochondrial Peptides and their Effects on Aging
二甲双胍调节的线粒体肽及其对衰老的影响
- 批准号:
10442624 - 财政年份:2020
- 资助金额:
$ 41.25万 - 项目类别:
Metformin-Regulated Mitochondrial Peptides and their Effects on Aging
二甲双胍调节的线粒体肽及其对衰老的影响
- 批准号:
10263310 - 财政年份:2020
- 资助金额:
$ 41.25万 - 项目类别:
Metformin-Regulated Mitochondrial Peptides and their Effects on Aging
二甲双胍调节的线粒体肽及其对衰老的影响
- 批准号:
10087404 - 财政年份:2020
- 资助金额:
$ 41.25万 - 项目类别:
Role of the Mitochondrial Peptide Humanin in Regulating Aging and Healthspan
线粒体肽护脑素在调节衰老和健康寿命中的作用
- 批准号:
10816721 - 财政年份:2018
- 资助金额:
$ 41.25万 - 项目类别:
Project 1: Disparities in Mitochondrial Peptidomics and Transcriptomics in Prostate Cancer
项目 1:前列腺癌线粒体肽组学和转录组学的差异
- 批准号:
10006117 - 财政年份:2018
- 资助金额:
$ 41.25万 - 项目类别:
Role of the Mitochondrial Peptide Humanin in Regulating Aging and Healthspan
线粒体肽护脑素在调节衰老和健康寿命中的作用
- 批准号:
10374750 - 财政年份:2018
- 资助金额:
$ 41.25万 - 项目类别:
Project 1: Disparities in Mitochondrial Peptidomics and Transcriptomics in Prostate Cancer
项目 1:前列腺癌线粒体肽组学和转录组学的差异
- 批准号:
10006099 - 财政年份:2018
- 资助金额:
$ 41.25万 - 项目类别:
Plasma Mitochondrial Peptide Assays as Biomarkers of Environmental Toxin Exposure
血浆线粒体肽测定作为环境毒素暴露的生物标志物
- 批准号:
8501469 - 财政年份:2011
- 资助金额:
$ 41.25万 - 项目类别:
Plasma Mitochondrial Peptide Assays as Biomarkers of Environmental Toxin Exposure
血浆线粒体肽测定作为环境毒素暴露的生物标志物
- 批准号:
8334612 - 财政年份:2011
- 资助金额:
$ 41.25万 - 项目类别:
Plasma Mitochondrial Peptide Assays as Biomarkers of Environmental Toxin Exposure
血浆线粒体肽测定作为环境毒素暴露的生物标志物
- 批准号:
8697052 - 财政年份:2011
- 资助金额:
$ 41.25万 - 项目类别:
相似海外基金
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10679095 - 财政年份:2022
- 资助金额:
$ 41.25万 - 项目类别:
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10526807 - 财政年份:2022
- 资助金额:
$ 41.25万 - 项目类别:
Epidemiologic studies of antidiabetic drugs and cancer risk: TMLE method, bias analysis and Mendelian randomization
抗糖尿病药物与癌症风险的流行病学研究:TMLE 方法、偏倚分析和孟德尔随机化
- 批准号:
21K10500 - 财政年份:2021
- 资助金额:
$ 41.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanical and histrogical analysis bone to implant contact in type2 diabetes rats model with antidiabetic drugs.
使用抗糖尿病药物的 2 型糖尿病大鼠模型中骨与种植体接触的机械和组织学分析。
- 批准号:
26462931 - 财政年份:2014
- 资助金额:
$ 41.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synergistic activity of combination thrapies using 4-hydroxisoleucine (ID1101) and other T2D antidiabetic drugs.
使用 4-羟基异亮氨酸 (ID1101) 和其他 T2D 抗糖尿病药物的联合疗法的协同活性。
- 批准号:
300267-2003 - 财政年份:2006
- 资助金额:
$ 41.25万 - 项目类别:
Industrial Research Fellowships
Synergistic activity of combination thrapies using 4-hydroxisoleucine (ID1101) and other T2D antidiabetic drugs.
使用 4-羟基异亮氨酸 (ID1101) 和其他 T2D 抗糖尿病药物的联合疗法的协同活性。
- 批准号:
300267-2003 - 财政年份:2005
- 资助金额:
$ 41.25万 - 项目类别:
Industrial Research Fellowships
Synergistic activity of combination thrapies using 4-hydroxisoleucine (ID1101) and other T2D antidiabetic drugs.
使用 4-羟基异亮氨酸 (ID1101) 和其他 T2D 抗糖尿病药物的联合疗法的协同活性。
- 批准号:
300267-2003 - 财政年份:2004
- 资助金额:
$ 41.25万 - 项目类别:
Industrial Research Fellowships